New VEGF antagonists as possible therapeutic agents in vascular disease.
2008, Expert Opin Investig Drugs. 2008 Sep;17(9):1301-14.
Slevin M, Kumar P, Wang Q, Kumar S, Gaffney J, Grau-Olivares M, Krupinski J.
Autors del centre relacionats: Slevin Mark.
Slevin M, Kumar P, Wang Q, Kumar S, Gaffney J, Grau-Olivares M, Krupinski J.
Autors del centre relacionats: Slevin Mark.
BACKGROUND: In this review we provide the reader with an analysis of the importance of VEGF in modulating the angiogenic process in vascular diseases. OBJECTIVES: We have described the key role of VEGF in the development of the major angiogenic diseases including ocular retinopathies, solid tumour growth and atherosclerotic plaque development. METHODS: Following a brief description of the disease, a detailed literature review of the mechanisms through which VEGF induces promotion of neovascularisation and current anti-VEGF therapies is provided for the reader. RESULTS/CONCLUSIONS: Current and future potential clinical therapies are discussed in particular concerning our thoughts on future directives involving adenoviral-mediated gene targeting, nanotechnology and combinational therapies.
Institut Català de Ciències Cardiovasculars
Hospital de la Santa Creu i Sant Pau, Pavelló del Convent
Sant Antoni Maria Claret, 167 08025 Barcelona
Espanya
T: +34 - 93 556 5900 F: +34 - 93 556 5559